Beijing Foyou Pharma (601089.SH): Diethylammonium adenosine enteric-coated tablets obtained drug registration certificate.

18:05 07/04/2026

Fuyuan Pharmaceutical (601089.SH) announced that recently, the company has received the Drug Registration Certificate for Adenosine Disodium Diammonium Enteric-coated Tablets [Specification: 0.5g (calculated as CHNOS)] issued by the National Medical Products Administration, approving the production of the drug.

Beijing Foyou Pharma (601089.SH) announced that the company recently received the "Drug Registration Certificate" (Certificate Number: 2026S00932) issued by the National Medical Products Administration for the production of adenine arabinoside enteric-coated tablets [specification: 0.5g (calculated as CHNOS)]. The adenine arabinoside enteric-coated tablets developed by ABBOTT were approved by the National Medical Products Administration in November 1996 and have been marketed in China. This product is suitable for intrahepatic cholestasis before and caused by liver cirrhosis. This drug is suitable for intrahepatic cholestasis during pregnancy.

PETROCHINA (00857) controlling shareholder's shareholding plan has been fully implemented, accumulating a total of 309 million shares held.

SINOPEC SEG (02386) signed an EPC engineering, procurement, and construction contract for the Kazakhstan Dineene and Rubber Project with a total contract value of approximately $1.093 billion.

E&P GLOBAL (01142) Court ruling revokes illegal coal mining license in Russia and will apply to withdraw the appeal

PETROCHINA (00857) controlling shareholder's shareholding plan has been fully implemented, accumulating a total of 309 million shares held.

SINOPEC SEG (02386) signed an EPC engineering, procurement, and construction contract for the Kazakhstan Dineene and Rubber Project with a total contract value of approximately $1.093 billion.

E&P GLOBAL (01142) Court ruling revokes illegal coal mining license in Russia and will apply to withdraw the appeal